Recently, it has been shown that treatments with dinaciclib, a CDK1, CDK2, CDK5, and CDK9 inhibitor, arrested cell cycle progression in the G2/M phase and induced programmed cell death in T-ALL cells [74]. Here, CDK2 is linked to acute lymphoblastic leukemia.